Seems I was on to something. Perhaps just a bit early. I mis-spoke in my earlier post attributing the change in trials to remdesivir. It was actually HCQ. So first CYDY allowed HCQ patients to enroll (previously excluded). Now they're going to trial w/ Remdesivir. Both are GILD drugs. Hmmmm

A few quotes from a while back:

Quote:

---

First we stopped disallowing those taking GILD's HC. Now it looks like we're going to enter trials with their drugs. Wonder what's next after we show stellar results against remdesivir?

---

Quote:

---

Things that make you wonder:
Note: Subject who were prescribed hydroxychloroquine or chloroquine with or without azithromycin for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents.

---

Quote:

---

I just wonder why suddenly they are ok with treating patients on GILD's drug. I would think at that point, it becomes quite hard to attribute MOA to either drug individually.

Am i overreaching in that the only reason to treat patients with both would be if there were discussions to treat patients with both drugs looking forward? Or do you think it's because they're trying to accelerate enrollment and a large swath of patients are currently being treated by HCQ?

---